Impaired fungal surveillance with Kennedy pathway activation drives acute liver failure, validated in preclinical models [0.03%]
肯尼迪途径活化导致肝病患者真菌监视功能受损，动物实验予以验证
Neha Sharma,Sushmita Pandey,Shvetank Sharma et al.
Neha Sharma et al.
Targeting the ASB3-CPT1A axis-a new player in combating metabolic dysfunction-associated steatotic liver disease [0.03%]
靶向ASB3-CPT1A轴——对抗与代谢功能障碍相关脂肪变性肝病的新策略
Yueying Yang,Ying Yang,Yan Lu
Yueying Yang
RAB25/GCN1 Signaling Promotes ER Stress to Mediate Alcohol-associated Liver Disease Progression [0.03%]
RAB25/GCN1信号促进内质网应激介导酒精性肝病进展
Xue-Wen Liu,Zi-Bin Zhan,Ze-Hua Li et al.
Xue-Wen Liu et al.
Background/aims: Endoplasmic reticulum (ER) stress in hepatocytes plays a causative role in alcohol-associated liver disease (ALD). The incomplete inhibition of ER stress by targeting canonical ER stress sensor proteins s...
Correspondence to editorial on "Dysfunction in CD8+ T Cells in Early-Stage HCC" by Qin et al.: New Insights into HCC Immunotherapy [0.03%]
针对秦等人的编辑部文章《肝细胞癌早期阶段CD8+t细胞功能障碍》的新见解：肝癌免疫治疗启示
Yang Kong,Xiaoqian Shen,Kun Xue et al.
Yang Kong et al.
Predictive Machine Learning Model in ICU Patients with Acute-on-Chronic Liver Failure and Two or More Organ Failures [0.03%]
急性-on-慢性肝功能衰竭并有两个或更多器官衰竭的ICU患者预测机器学习模型
Yee Hui Yeo,Mengyi Zhang,Martin S McCoy et al.
Yee Hui Yeo et al.
Background: Prediction of short-term mortality in patients with acute-on-chronic liver failure (ACLF) admitted in the intensive care unit (ICU) may enhance effective management. ...
Association of bile acid composition with synthetic pathways and efficacy of bezafibrate in cholestatic liver disease [0.03%]
胆汁酸组成与其合成途径及bezafibrate在肝胆疾病中的疗效之间的关联性分析
Manami Iida,Atsuko Higashida,Shuichi Ohtomo et al.
Manami Iida et al.
Background & aims: Bezafibrate (BZF), a dual peroxisome proliferator-activated receptor/pregnane X receptor agonist, has demonstrated efficacy in combination with ursodeoxycholic acid (UDCA) for primary biliary cholangiti...
Reply to Letter on "Sex-Specific Trends and Demographic vs Epidemiologic Drivers of Alcohol-Related Cirrhosis in the U.S., 2021-2040" [0.03%]
关于“美国2021至2040年酒精性肝硬化的性别差异及其人口与流行病学驱动因素”的来信的回信
Pojsakorn Danpanichkul,Luis Antonio Diaz,Juan Pablo Arab et al.
Pojsakorn Danpanichkul et al.
SAFE Score in Chronic Liver Diseases: A Tool for Risk Enrichment and Personalized Surveillance [0.03%]
慢性肝病中的SAFE评分：用于风险分层和个性化监测的工具
Tung-Hung Su,Jia-Horng Kao
Tung-Hung Su
An editorial on "Human cytomegalovirus reactivation in cirrhosis patients with acute decompensation" by Hong et al. Title: Human cytomegalovirus reactivation in decompensated cirrhosis: marker of immunosuppression or contributor to severity? [0.03%]
人巨细胞病毒再激活与肝硬化失代偿：免疫抑制的标志还是病情加重的因素？
Zhujun Cao,Richard Moreau
Zhujun Cao